[Endoluminal treatment of gastro-oesophageal reflux disease: too early to determine a clear role].
Gastro-oesophageal reflux disease is a chronic disorder. The most important therapeutic measure is long-term pharmacological acid inhibition. Anti-reflux surgery plays a role in cases where pharmacological treatment fails. A new development is endoluminal treatment for reflux disorders. The various methods used are based on one of the following principles: radiofrequency ablation, gastroplication and implantation of a bulking agent. Short-term results with endoluminal treatment are not very positive and longer-term results have been disappointing so far. Results from randomised studies are still largely unavailable. Longer follow-up and controlled randomised studies are needed before a well-founded judgment can be made regarding the place of endoluminal treatment in the therapeutic armamentarium.
Peters
F T M
FT
Universitair Medisch Centrum Groningen, afd. Maag-, Darm- en Leverziekten, Groningen. f.t.m.peters@int.umcg.nl
Kleibeuker
J H
JH
D000863:Antacids / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016145:Endoscopy, Digestive System / Q000379:methods*; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D016896:Treatment Outcome
D000863:Antacids